Search
Powered By HealthLine
Special Offers
TV Specials
 Learn about an Effective Alzheimer's Medication
 Bipolar Education Health Center
 Osteoarthritis of the Knee Solution Center
 Heartburn Education Center
 Breast Cancer Health Center
 Crohn's Disease Health Center
 Schizophrenia Education Center
Top Features
 Depression
 Schizophrenia
 Breast Cancer
 Bipolar
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
Drug DescriptionSide Effects & Drug InteractionsWarnings & Precautions
Clinical PharmacologyOverdosage & ContraindicationsIndications & DosagePatient Info

Altace

[Ramipril]

Heart Failure Post Myocardial Infarction Adverse reactions (except laboratory abnormalities) considered possibly/ probably related to study drug that occurred in more than one percent of patients and more frequently on ramipril are shown below. The inci-dences represent the experiences from the AIRE study. The follow-up time was between 6 and 46 months for this study.

HOPE Study:

Text Continues Below



Safety data in the HOPE trial were collected as reasons for discontinuation or temporary interruption of treat-ment. The incidence of cough was similar to that seen in the AIRE trial. The rate of angioedema was the same as in previous clinical trials (see WARNINGS).

Other adverse experiences reported in controlled clinical trials (in less than 1% of ramipril patients), or rarer events seen in postmarketing experience, include the following (in some, a causal relationship to drug use is uncertain):

Body As a Whole:

Anaphylactoid reactions. (See WARNINGS.)

Cardiovascular:

Angina/ chest pain, arrhythmias including bradycardia or tachycardia, cardiac arrest, con-gestive heart failure, symptomatic hypotension (reported in 0.5% of patients in US trials) (See WARNINGS and PRECAUTIONS), syncope, palpitations, transient ischemia attack, and myocardial infarction or cerebrovascular accident possibly due to excessive hypotension.

Hematologic:

Pancytopenia, hemolytic anemia and thrombocytopenia.

Renal:

Some hypertensive patients with no apparent pre-existing renal disease have developed minor, usu-ally transient, increases in blood urea nitrogen and serum creatinine when taking ALTACE, particularly when ALTACE was given concomitantly with a diuretic. (See WARNINGS.) Acute renal failure.

Angioneurotic Edema:

Angioneurotic edema has been reported in 0.3% of patients in US clinical trials. (See WARNINGS.)

Gastrointestinal:

Pancreatitis, abdominal pain (sometimes with enzyme changes suggesting pancreatitis), anorexia, constipation, diarrhea, dry mouth, dyspepsia, dysphagia, gastroenteritis, hepatitis, increased saliva-tion and taste disturbance.

Page:  << Prev | 1 | 2 | 3 | 4 | Next >>







New Features

New ADHD Site!


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service